JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB152001

Human IgE protein

Be the first to review this product! Submit a review

|

(1 Publication)

Human IgE protein is a Human Full Length protein with >90% purity, < 25 EU/mg endotoxin level and suitable for ELISA, ICC and SDS-PAGE. The predicted molecular weight of ab152001 protein is 185 kDa.

- Save time and ensure accurate results - use our IgE protein as an isotype control
- No cross-reaction from other immunoglobulin isotypes

View Alternative Names

Immunoglobulin heavy constant epsilon, Ig epsilon chain C region, Ig epsilon chain C region ND, IGHE

1 Images
SDS-PAGE - Human IgE protein (AB152001)
  • SDS-PAGE

Unknown

SDS-PAGE - Human IgE protein (AB152001)

SDS-PAGE analysis of ab152001.
Lane 1 : Marker
Lane 2 : purified Human IgE (ab152001), MW 185 kDa
Lane 3 : Myeloma source IgE, purified from Human serum.

Key facts

Purity

>90% SDS-PAGE

Endotoxin level

< 25 EU/mg

Expression system

Synthetic

Tags

Tag free

Applications

SDS-PAGE, ELISA, ICC

applications

Biologically active

No

Accession

P01854

Animal free

No

Carrier free

No

Species

Human

Storage buffer

pH: 7.4 Preservative: 0.09% Sodium azide Constituents: PBS, 0.88% Sodium chloride

storage-buffer

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "ELISA": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "ICC": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p>Observed band of ~185kDa</p>" } } }

Product details

Ensure the validity of your result using our human IgE protein ab152001 as a positive control in SDS-PAGE.

Analyze your ELISA data using the IgE ab152001 protein to generate and plot a standard curve.


Check out our protein gel staining guide for SDS-PAGE here

Check out our ELISA protocol for more information here.


ab152001 is purified Human IgE with kappa light chains produced in vitro from a monoclonal hybridoma.

Original material is obtained from a healthy donor tested negative by US-FDA approved tests against HIV, HCV and Hepatitis B. Must be handled as potentially infectious as all Human material.

Sequence info

[{"sequence":"","proteinLength":"Full Length","predictedMolecularWeight":null,"actualMolecularWeight":null,"aminoAcidEnd":0,"aminoAcidStart":0,"nature":"","expressionSystem":null,"accessionNumber":"P01854","tags":[]}]

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
False

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The IgE protein [also known as immunoglobulin E] is a type of antibody with a molecular mass of approximately 190 kDa. IgE is expressed primarily on the surface of mast cells and basophils. It plays a central role in the immune system by binding to allergens and triggering the release of inflammatory mediators from mast cells and basophils. IgE's high-affinity binding to its receptor FcεRI on these effector cells facilitates this process. IgE's activity is central to initiating immediate hypersensitivity reactions which are a part of the body's immune response.
Biological function summary

The IgE protein functions as a mediator in allergic reactions. It does not operate as part of a complex but directly interacts with allergens and the IgE-specific receptors on immune cells. IgE's role is important in defense against parasitic infections where it performs a protective function by promoting eosinophil activation and degranulation. This action helps the body to expel the parasites. In the absence of parasitic infection IgE's function translates into its role in allergic responses where it becomes responsible for the symptoms associated with allergic diseases.

Pathways

IgE is an important player in the immune response pathway. The protein interacts with allergy-related pathways such as the T helper 2 (Th2) pathway. IgE's role in this pathway involves cooperation with cytokines notably IL-4 and IL-13 which are produced by Th2 cells and promote IgE synthesis in B cells. Also IgE is linked to the FcεRI receptor signaling pathway that initiates the release of histamines and other mediators when IgE binds to an allergen leading to an allergic response.

IgE is closely linked to allergic conditions like asthma and allergic rhinitis. These conditions result from IgE-mediated inflammatory responses that affect the respiratory system. In asthma IgE antibodies play a role in airway inflammation and hyperreactivity by promoting the activation of multiple immune cells including eosinophils and mast cells. IgE's involvement in allergic rhinitis manifests through similar mechanisms with nasal inflammation and irritation. IgE's interaction with other proteins such as histamine-releasing factor exacerbates these conditions by increasing the release of histamine which intensifies the allergic symptoms.

Specifications

Form

Liquid

Additional notes

Human IgE full length protein was purified by Protein L chromatography. As the IgE comes from a monoclonal cell line, there is no contamination of antibodies of other isotypes. The remaining contaminants are mainly components from Foetal Bovine Serum.

General info

Function

Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed : 20176268, PubMed : 22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed : 17576170, PubMed : 20176268).. Isoform 1. Constant region of secreted IgE, also known as the Fc region of IgE antibody. Mediates IgE effector functions on myeloid and lymphoid cells primarily via two Fc receptors, the high-affinity IgE Fc receptor complex/FCER1A : MS4A2 : FCGR1A and the low-affinity FCER2 receptor, which upon antigen/allergen cross-linking initiate signaling pathways that lead to immune cell activation and differentiation (PubMed : 2167225, PubMed : 25629393, PubMed : 33840121, PubMed : 7544003, PubMed : 8114916, PubMed : 8551243). Triggers the immediate hypersensitivity response to allergens as a host defense mechanism against helminth parasites, pathogenic bacteria and venom toxicity. When dysregulated, it can elicit harmful life-threatening allergic and anaphylactic reactions (PubMed : 25629393, PubMed : 33840121, PubMed : 7544003, PubMed : 8114916, PubMed : 8551243). Stimulates the high-affinity IgE Fc receptor complex/FCER1A : MS4A2 : FCGR1A on mast cells, basophils and eosinophils leading to secretion of vasoactive amines, lipid mediators and cytokines that contribute to inflammatory response, tissue remodeling and cytotoxicity against microbes (PubMed : 25629393, PubMed : 8114916, PubMed : 8551243). On macrophages, cross-linking of FCER2 by IgE immune complexes induces intracellular killing of parasites through activation of L-Arginine-nitric oxide pathway (PubMed : 7544003). Activates macrophages to kill tumor cells via antigen-specific antibody-dependent cytotoxicity (ADCC). Triggers differentiation of quiescent M0 macrophages toward M1 state and reprograms M2 macrophages toward a proinflammatory state with antitumor functions (PubMed : 30956175). Stimulates FCER2 on B cells and initiates IgE-dependent antigen uptake and presentation to T cells (PubMed : 2167225).. Isoform 2. Constant region of membrane-bound IgE (long mIgE), part of the B cell receptor complex (BCR). Upon antigen cross-linking triggers quick BCR signaling, ensuring survival of IgE-switched B cells and differentiation into plasma cells, thus regulating both primary and memory IgE responses.. Isoform 3. Constant region of membrane-bound IgE (short mIgE), part of the B cell receptor complex (BCR). Upon antigen cross-linking initiates slower but sustained BCR signaling that negatively regulates mature B cell proliferation.

Product protocols

Target data

Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed : 20176268, PubMed : 22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed : 17576170, PubMed : 20176268).. Isoform 1. Constant region of secreted IgE, also known as the Fc region of IgE antibody. Mediates IgE effector functions on myeloid and lymphoid cells primarily via two Fc receptors, the high-affinity IgE Fc receptor complex/FCER1A : MS4A2 : FCGR1A and the low-affinity FCER2 receptor, which upon antigen/allergen cross-linking initiate signaling pathways that lead to immune cell activation and differentiation (PubMed : 2167225, PubMed : 25629393, PubMed : 33840121, PubMed : 7544003, PubMed : 8114916, PubMed : 8551243). Triggers the immediate hypersensitivity response to allergens as a host defense mechanism against helminth parasites, pathogenic bacteria and venom toxicity. When dysregulated, it can elicit harmful life-threatening allergic and anaphylactic reactions (PubMed : 25629393, PubMed : 33840121, PubMed : 7544003, PubMed : 8114916, PubMed : 8551243). Stimulates the high-affinity IgE Fc receptor complex/FCER1A : MS4A2 : FCGR1A on mast cells, basophils and eosinophils leading to secretion of vasoactive amines, lipid mediators and cytokines that contribute to inflammatory response, tissue remodeling and cytotoxicity against microbes (PubMed : 25629393, PubMed : 8114916, PubMed : 8551243). On macrophages, cross-linking of FCER2 by IgE immune complexes induces intracellular killing of parasites through activation of L-Arginine-nitric oxide pathway (PubMed : 7544003). Activates macrophages to kill tumor cells via antigen-specific antibody-dependent cytotoxicity (ADCC). Triggers differentiation of quiescent M0 macrophages toward M1 state and reprograms M2 macrophages toward a proinflammatory state with antitumor functions (PubMed : 30956175). Stimulates FCER2 on B cells and initiates IgE-dependent antigen uptake and presentation to T cells (PubMed : 2167225).. Isoform 2. Constant region of membrane-bound IgE (long mIgE), part of the B cell receptor complex (BCR). Upon antigen cross-linking triggers quick BCR signaling, ensuring survival of IgE-switched B cells and differentiation into plasma cells, thus regulating both primary and memory IgE responses.. Isoform 3. Constant region of membrane-bound IgE (short mIgE), part of the B cell receptor complex (BCR). Upon antigen cross-linking initiates slower but sustained BCR signaling that negatively regulates mature B cell proliferation.
See full target information IGHE

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Translational oncology 2:1-7 PubMed19252746

2009

COX-2 Inhibition Combined with Radiation Reduces Orthotopic Glioma Outgrowth by Targeting the Tumor Vasculature.

Applications

Unspecified application

Species

Unspecified reactive species

Michiel Wagemakers,Gesiena E van der Wal,Rosa Cuberes,Inés Alvarez,Eva Ma Andrés,Jordi Buxens,José M Vela,Henk Moorlag,Jan Jakob A Mooij,Grietje Molema
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com